Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Monoclonal Antibody Therapeutics Market By Product, By Type, By Application, By End User, and Region Forecast 2020-2031
Monoclonal Antibody Therapeutics Market By Product, By Type, By Application, By End User, and Region Forecast 2020-2031
Monoclonal Antibody Therapeutic Market size was valued at US$ 254.9 billion in 2024 and is expected to reach US$ 657.6 billion by 2031, growing at a significant CAGR of 14.5% from 2025-2031. There will be around 70 monoclonal antibody products in the market by 2020 and the sales are estimated to be million which is considered as the key driver. Restrain which hung the global monoclonal antibody therapeutic are many drugs like Abagovomab, and Actoxumab in phase II and still waiting for approval which can be considered as a key challenge. The biggest opportunity is opened up due to various chronic disorders hence huge growth in the market is been expected. Monoclonal antibodies are a type of immunotherapy that is created in a lab and consists of several copies of a single antibody. The US Food and Drug Administration has approved several monoclonal antibodies to treat inflammation, cancer, and other disorders (FDA). Monoclonal antibodies are classified as murine, chimeric, humanized, or human, depending on the source. Murine antibodies are produced solely from a murine source, whereas chimeric antibodies have variable murine origins and constant human origins.
Study Period
2025-2031Base Year
2024CAGR
14.5%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
It is noticed that the market is influenced mainly by the number of cancer patients which is the key factor causing the monoclonal antibody market to grow. According to WHO (World Health Organization) around 18.1 million new cases have been reported and 96 million death rates have been observed due to cancer. The market is considered to be a lifesaving innovation and the market is estimated to be valued in huge amount by 2026. 100 monoclonal antibodies have been designated as drug and 64 monoclonal antibodies have been approved by USFDA. There are a lot of pipeline drugs related to cancer waiting for the approval and that would intensify the growth of the market.
North America contributed major revenue followed by Europe and Asia Pacific. In 2019, North America region accounted huge growth rate and is anticipated to grow with a forecast year. For instance, developed and established healthcare infrastructure support from the government for R&D activity may contribute the revenue growth of market. According to Centre for Disease Control and Prevention 6 in 12 adults in US have chronic disease. Europe is booming on the perspective of innovative products the market share to both together is estimated as 65%. However, it was evident that the market gaining interest in developing nations. Asia pacific is growing on the perspective of faster growing market players which boost the market.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 254.9 billion |
|
Market Size in 2031 |
US$ 657.6 billion |
|
Market CAGR |
14.5% |
|
By Product Type |
|
|
By Type |
|
|
By End-User |
|
|
By Region |
|
Download Free Sample Report
Monoclonal antibody therapeutic market size was valued at US$ 254.9 billion in 2024 and is expected to reach US$ 657.6 billion by 2031, growing at a CAGR of 14.5%.
ImmunoGen, Inc., Bayer AG, Biogen, Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Amgen, Inc., Pfizer Inc., Sanofi, Novartis AG, Merck, AbbVie
Asia Pacific is the fastest-growing region for monoclonal antibody therapeutics market
| 1.Executive Summary |
| 2.Global Monoclonal Antibody Therapeutics Market Introduction |
| 2.1.Global Monoclonal Antibody Therapeutics Market - Taxonomy |
| 2.2.Global Monoclonal Antibody Therapeutics Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Type |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Monoclonal Antibody Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Monoclonal Antibody Therapeutics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Monoclonal Antibody Therapeutics Market By Product Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Naked, Fusion Protein |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Antibody Fragment |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Conjugate |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Multi-specific |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Monoclonal Antibody Therapeutics Market By Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Human Monoclonal Antibody |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Humanized Monoclonal Antibody |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Chimeric Monoclonal Antibody |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Murine Monoclonal Antibody |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Monoclonal Antibody Therapeutics Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Hospital Pharmacy |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacy |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacy |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Monoclonal Antibody Therapeutics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Product Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Naked, Fusion Protein |
| 9.1.2.Antibody Fragment |
| 9.1.3.Conjugate |
| 9.1.4.Multi-specific |
| 9.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Human Monoclonal Antibody |
| 9.2.2.Humanized Monoclonal Antibody |
| 9.2.3.Chimeric Monoclonal Antibody |
| 9.2.4.Murine Monoclonal Antibody |
| 9.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacy |
| 9.3.2.Retail Pharmacy |
| 9.3.3.Online Pharmacy |
| 9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Naked, Fusion Protein |
| 10.1.2.Antibody Fragment |
| 10.1.3.Conjugate |
| 10.1.4.Multi-specific |
| 10.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Human Monoclonal Antibody |
| 10.2.2.Humanized Monoclonal Antibody |
| 10.2.3.Chimeric Monoclonal Antibody |
| 10.2.4.Murine Monoclonal Antibody |
| 10.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacy |
| 10.3.2.Retail Pharmacy |
| 10.3.3.Online Pharmacy |
| 10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Naked, Fusion Protein |
| 11.1.2.Antibody Fragment |
| 11.1.3.Conjugate |
| 11.1.4.Multi-specific |
| 11.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Human Monoclonal Antibody |
| 11.2.2.Humanized Monoclonal Antibody |
| 11.2.3.Chimeric Monoclonal Antibody |
| 11.2.4.Murine Monoclonal Antibody |
| 11.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacy |
| 11.3.2.Retail Pharmacy |
| 11.3.3.Online Pharmacy |
| 11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Naked, Fusion Protein |
| 12.1.2.Antibody Fragment |
| 12.1.3.Conjugate |
| 12.1.4.Multi-specific |
| 12.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Human Monoclonal Antibody |
| 12.2.2.Humanized Monoclonal Antibody |
| 12.2.3.Chimeric Monoclonal Antibody |
| 12.2.4.Murine Monoclonal Antibody |
| 12.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacy |
| 12.3.2.Retail Pharmacy |
| 12.3.3.Online Pharmacy |
| 12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Naked, Fusion Protein |
| 13.1.2.Antibody Fragment |
| 13.1.3.Conjugate |
| 13.1.4.Multi-specific |
| 13.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Human Monoclonal Antibody |
| 13.2.2.Humanized Monoclonal Antibody |
| 13.2.3.Chimeric Monoclonal Antibody |
| 13.2.4.Murine Monoclonal Antibody |
| 13.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacy |
| 13.3.2.Retail Pharmacy |
| 13.3.3.Online Pharmacy |
| 13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.ImmunoGen, Inc. |
| 14.2.2.Bayer AG |
| 14.2.3.Biogen |
| 14.2.4.Hoffmann-La Roche Ltd. |
| 14.2.5.GlaxoSmithKline Plc |
| 14.2.6.Amgen, Inc. |
| 14.2.7.Pfizer Inc. |
| 14.2.8.Sanofi |
| 14.2.9.Novartis AG |
| 14.2.10.Merck |
| 14.2.11.AbbVie |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.